|
Curetracks Leadership:
|
 |
|
Ronen Viner
Founder
The initiator of the project and the developer of its execution strategy.
Vast experience in business-strategy, systemic-innovation and value-creation, as a Vice President at a leading strategy consultancy in Israel.
An extensive track-record in managing highly-complex analytical projects in various sectors (including in the Pharmaceutical and Bio-Medical industries).
Holding a B.Sc. in Industrial Engineering and Management and an MBA, both from the Technion – Israel Institute of Technology.
|
| |
Scientific and Medical Advisory Board
|
 |
|
Prof. Jacob Shoham
MD, PhD. - Chairman
Professor Emeritus at Bar-Ilan University and a certified diplomate of Internal Medicine in the United States and in Israel, with additional specialty in Medical Oncology from the U.S. Has completed studies in Nutritional Medicine, Medical Ecology, Clinical Immunology, Chinese and Western Herbal Medicine, Psycho-oncology, Medical hypnosis and Mind-Body Medicine. His research focus is in the fields of cancer and immunology. In the past served as a senior physician at the Sheba Medical Center and Vice-President of R&D at Interpharm, a pioneering Israeli pharmaceutical company. Prof. Shoham was a senior advisor to the Israel National Council for Research and Development and a member of the Israeli National Committee for Biomedical Research Policy. He is currently researching cancer therapies at Bar-Ilan University and developing the conceptual and practical foundations of Health-Promoting Medicine, emphasizing the recruitment of the inner healing forces. Prof. Shoham is Chairman of the "KaMaH" Association's Executive Committee and serves as the Center's Medical and Scientific Director.
|
 |
|
Professor Yechezkel (Chezy) Barenholz
Head of Membrane and Liposome Research Lab, Hebrew University Hadassah Medical School
Professor Barenholz (Daniel G. Miller Professor in Cancer Research) received his Ph.D. at the Hebrew University-Hadassah Medical School, Jerusalem in 1971. He is on the faculty of the Hebrew University since 1968 and was promoted to a Professor on 1981. He was a visiting Professor from 1973-2010 at numerous universities across the world.
His current basic research focuses on composition, structure, function relationships of biological membranes with special focus and contributions related to sphingolipids. His applied research deals with development of drug delivery systems (DDS) and drugs based on such DDS. This is exemplified by the development of the anticancer drug DoxilTM (together with Professor Alberto Gabizon and SEQUUS Pharmaceuticals, Menlo Park CA, USA), the first FDA approved nano drug and the first FDA approved liposomal drug (1995), distributed all over the world by Johnson & Johnson, with annual sales exceeding half a Billion dollars. Professor Barenholz with help of others founded (based on Barenholz inventions) 3 start up companies (NasVax Ltd, a vaccines' developing company, Moebius medical which develops liposomes' based medical device for treatment of osteoarthritis, and LipoCure Ltd developing liposomal nano drugs for treatment of cancer and inflammatory diseases). Professor Barenholz is a coauthor in more than 350 scientific publications and a co-inventor in more than 30 approved patent families. He was an executive editor of Progress in Lipid Research and he is on the editorial board of 4 scientific journals. Professor Barenholz was awarded few prizes including twice the Kaye award (1995 & 1997), Alec D. Bangham (the Liposome field founder) award (1998), and Teva Founders Prize (2001). On 2003 Professor Barenholz founded (from Doxil royalties) the "Barenholz Prize" for Israeli Ph.D. students to encourage excellence and innovation in applied science of Israeli students.
|
 |
|
Prof. Keith Block
MD
Regarded as a pioneer in the field of integrative cancer treatment and as one of the most prominent figures in integrative medicine in general in the U.S.
He is the founder and head of the Center for Integrative Treatment of Cancer in Evanston, Illinois and serves as Director of the Integrative Medical Education Program, University of Illinois College of Medicine. In addition, he serves as a member of the Editorial Board for Physician Data Query, CAM, National Cancer Institute and as the Editor-in-Chief of the medical-scientific journal "Integrative Cancer Therapies"
|
 |
|
Prof. Harold J. Brenner
MB, ChB, DMRT, FRCR.
Regarded as one of Israel's most prominent oncologists. Former Director of the Oncology Institute at the Sheba Tel Hashomer Medical Center for 35 years (until 2003); Chairman, Section of Oncology, Tel Aviv University and of the Israel National Examination Board for Oncology. He was the former Advisor to the Ministry of Health on Oncology and a recipient of the Sheba Prize for Excellence in Medicine. Currently he is the Medical Director of the Eshkol Community Medical Services and senior oncology consultant at the Rabin Medical Center's Davidoff Comprehensive Cancer Center. Has been recently invited to establish a new Oncology Institute in Shanghai, China
|
 |
|
Prof. Uri Nir
PhD
A full professor at Bar Ilan University and currently serves as the Dean of the Everard and Mina Goodman Faculty of Life Sciences and as Head of the Nano-medicine Center of the University. He has completed his PhD thesis at the Wiezmann Institute of Science and a fellowship in the University of California at San Francisco. Prof. Nir is a member of the Research Council of the Israel Cancer Association and of the Grant Evaluation Committee of the Israel Association for Cancer Research. His current research focus is on novel targets for anti-cancer drugs.
|
| We are backed by researchers and medical practitioners that are versed in both conventional and complementary medicine. |
|
|
|
